Aeolus Pharmaceuticals, Inc.
Other OTCTotal Valuation
Aeolus Pharmaceuticals, Inc. carries a market capitalization of 15,209.00, placing it among publicly traded companies globally. Its enterprise value stands at 13.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 15,209.00 |
| Enterprise Value | 13.41M |
Share Statistics
Aeolus Pharmaceuticals, Inc. currently has 152.09M shares outstanding.
| Shares Outstanding | 152.09M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 17.91, and the price-to-book ratio stands at -0.07.
| PE Ratio | N/A |
| PS Ratio | 17.91 |
| PB Ratio | -0.07 |
| P/TBV Ratio | 66.73 |
| P/FCF Ratio | -4.12 |
| P/OCF Ratio | -4.12 |
Enterprise Valuation
| EV / Sales | 17.39 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Aeolus Pharmaceuticals, Inc. maintains a current ratio of 1.30, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.30 |
| Quick Ratio | 1.22 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -144.49 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Income Statement
Over the trailing twelve months, Aeolus Pharmaceuticals, Inc. generated 771,000.00 in revenue and converted that into -4.09M in net income, yielding earnings per share of -0.03. EBITDA reached -4.09M, while operating income came in at -4.09M.
| Revenue | 771,000.00 |
| Gross Profit | N/A |
| Operating Income | -4.09M |
| Pretax Income | -4.09M |
| Net Income | -4.09M |
| EBITDA | -4.09M |
| EBIT | -4.09M |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
Total book value stands at -191.74M, with working capital of 175,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 403,000.00 |
| Total Debt | N/A |
| Net Debt | -403,000.00 |
| Equity (Book Value) | -191.74M |
| Book Value Per Share | -1.26 |
| Working Capital | 175,000.00 |
Cash Flow
Aeolus Pharmaceuticals, Inc. produced -3.35M in operating cash flow over the past twelve months.
| Operating Cash Flow | -3.35M |
| Capital Expenditures | N/A |
| Free Cash Flow | -3.35M |
| FCF Per Share | -0.02 |
Margins
Aeolus Pharmaceuticals, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -531.00 and net profit margin of -531.00 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -531.00 |
| Pretax Margin | -531.00 |
| Profit Margin | -531.00 |
| EBITDA Margin | -531.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -24.28 |
Stock Splits
Aeolus Pharmaceuticals, Inc.'s most recent stock split took place on July 16, 2004 with a 10:1 split ratio.
| Last Split Date | 7/16/2004 |
| Split Ratio | 10:1 |
Scores
Aeolus Pharmaceuticals, Inc. posts an Altman Z-Score of -342.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -342.42 |